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Gastroesophageal reflux disease (GERD) is a common disorder, known to affect about 20% of the Western population.
Although conventional medical or surgical treatment has proven effective, there is certainly room for improvements.
As only 10% of GERD patients are finally treated by antireflux surgery, a large therapeutic window exists. This
treatment gap consists of patients who are not effectively treated with proton pump inhibitor but do not want to run
the potential risks of conventional surgery. During the last two decades, several novel and intriguing options for the
surgical treatment of GERD have been introduced and found their way into clinical use. The following summary will
give an update of certain alternative therapeutic options to treat GERD or its pathological consequences.
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Introduction
Gastroesophageal reflux disease (GERD) is a com-
mon disorder, known to affect about 20% of the
Western population.1 Although symptomatic ther-
apy with proton pump inhibitors (PPIs) or causative
therapy by conventional antireflux surgery has been
shown to be effective, there is certainly room for
improvements. PPI therapy does treat some symp-
toms of GERD but not its cause. Even if these
symptoms respond to medical therapy, PPIs have
come under scrutiny due to eventual long-term
adverse events.2 Although several clinical stud-
ies have shown a cancer-protective effect of PPI,
data remain contradictory.3 As apparently only a
very small proportion of GERD patients are finally
treated by conventional antireflux surgery, a large
therapeutic window of patients, who are not effec-
tively treated with PPI but do not want to run the
potential risks of conventional surgery, remains.
The last two decades have seen the development
and clinical use of several novel and intriguing
options to treat GERD and its consequences. These
methods either aim to restore the esophageal cellu-
lar barrier after reflux-induced mucosal damage or
aim to restore the physiological reflux barrier (i.e.,
the lower esophageal sphincter) itself. Radiofre-
quency ablation (RFA) of esophageal mucosa has
become a mainstay within the treatment of reflux-
induced esophageal mucosal dysplasia as well as
early esophageal cancer, but the optimal time of
either before or after potentially necessary antire-
flux surgery remains a matter of debate. Addition-
ally, alternative endoscopic or surgical therapeu-
tic options, such as endoscopic plication of the
gastric fundus, magnetic sphincter augmentation,
or even the electric sphincter augmentation, have
been developed. These therapeutic options could
challenge standard antireflux surgery but foremost
might provide a less destructive option to treat
doi: 10.1111/nyas.13851
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GERD, providing the opportunity of personalized
surgical antireflux therapy.
Reflux and mucosal integrity
GERD impairs the quality of life due to the symp-
toms and an increased cancer risk in those with
columnar lined esophagus and Barrett’s esopha-
gus (BE) (0.5% per year).4,5 GERD appears to
develop as a progressive disease and also results
from life style-induced dysfunction of the antire-
flux mechanism (i.e., the lower esophageal sphinc-
ter and the anchorage of the esophagus within the
diaphragm).6 As a consequence, reflux provokes an
inflammatory response, which in turn loosens the
epithelial integrity.7–9 Electrophysiology, that is,
transepithelial resistance and impedance, repre-
sents a well-accepted measure for the assessment of
the integrity of the esophageal squamous epithe-
lium and can be applied on esophageal biopsies
in vitro and in vivo during esophageal impedance
monitoring.7–10
Recent impedance studies have demonstrated
that acid reflux impairs the esophageal resistance,
that is, integrity of the epithelium.7–10 The elec-
tron microscopic finding of enlarged intercellular
spaces parallels these findings. Furthermore, elec-
trical resistance is a good measure to monitor the
recovery of the esophageal mucosa after RFA. RFA,
used to eliminate BE with increased cancer risk (i.e.,
dysplasia and early cancer), eradicates the BE posi-
tive columnar lined esophagus with radiofrequency
energy. Several weeks following RFA, neo-squamous
epithelium reveals the ablated segments of the
esophagus. Although the electrical resistance of the
neo-squamous epithelium is significantly increased
compared to Barrett’s mucosa, it is significantly
lower compared to normal squamous lined mucosa
of the esophagus. Since patients receive high-dose
PPI therapy after RFA, these resistance differences
between normal and neo-squamous epithelium are
suggested to be attributed to the lack of elimination
of the reflux per se. Going in line with this notion,
a recent study found that elimination of the reflux
after effective fundoplication is more effective to
restore the electrical resistance of the esophagus.11
Taken together, the above studies show that elec-
trical resistance serves as a sensitive measure to mon-
itor the integrity of the esophageal epithelium before
and after medical or surgical therapy of GERD and
Figure 1. Gastroesophageal reflux activates an inflamma-
tory response involving epithelial cells, nerve, immune cells,
endothelial cells, and myofibroblasts. Acid and bile activate
the release of proinflammatory mediators (substance P, neu-
rotensin, and vasoactive intestinal peptide) from squamous
epithelial cells and nerve cells, which in turn orchestrate the
stimulation of immune cells (mast cells and leucocytes), myofi-
broblasts, and endothelial cells within the mucosa. As a con-
sequence, these cells (mast cells, etc.) amplify and extend the
mucosal inflammation by release of histamine, substance P, neu-
rotensin, serotonin, prostaglandins, etc. Over time, this multi-
mediator response involves the mucosa and submucosa of the
esophagus, and mediates the perception of symptoms (heart-
burn, etc.). This results in the development of genetic changes,
such as upregulation of gene transcription factors (e.g., CDX2),
driving the formation of columnar lined esophagus ± intestinal
metaplasia, dysplasia, and cancer.
BE.7–11 Conceptually, GERD results from a reflux-
induced orchestration of an inflammatory response,
involving epithelial, nerve, inflammatory, and mus-
cle cells within the esophageal mucosa4–6 (Fig. 1).
Shall we ablate patients before or after
antireflux surgery?
Endoscopic RFA today represents a well-established,
safe, and effective procedure for the treatment of
BE12 (Fig. 2). Choice of adjunct treatment to RFA
emerges as an important clinical issue, due to the
fact that recurrence of BE after complete eradica-
tion (CE) of intestinal metaplasia (IM) or dysplasia
may occur. A systematic review and meta-analysis
indicted that approximately 13% of RFA patients
will have BE recurrence after previously achieved
CE.13
Up to now, there are no randomized trials com-
paring the role of antireflux surgery (ARS) and PPIs
on RFA outcomes. Several publications showed a
possible protective role of ARS after successful RFA
treatment. One of the studies revealed that patients
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Figure 2. Schematic drawing of the LINX system.
with IM and dysplastic BE who were submitted
to ARS after RFA have statistically lower incidence
of persistent and recurrent BE opposed to those
receiving PPI’s on a 1-year follow-up.14 In another
study, which prospectively evaluated BE recurrence
after RFA, ARS proved to be superior over the PPI
regimen in patients with long BE (4 cm), with
significantly lower incidence on a 3-year follow-
up.15 Recent data that covered a 5-year follow-
up of patients included in randomized Ablation
of Intestinal Metaplasia Containing Dysplasia trial
(AIM Dysplasia Trial) pointed out that recurrence
of BE is most frequent in the first year following
RFA.16 Concerning the data available so far, we have
to think of optimal prevention strategy in the early
follow-up period and consider the ARS in selected
group of patients.
Today, no data comparing the fundoplication
prior or after the RFA are available. However,
some technical difficulties when prior fundoplica-
tion existed have been shown, mostly reflected as
inability of proper calibration and therefore opti-
mal ablation.17 One of the potential benefits of
ARS in addition to RFA procedure might be in
a challenging group of patients with major hiatal
hernias and dilated distal esophagus, who mostly
have long segments of BE. These patients can be
treated by employing concomitant ARS and RFA.18
In this manner, after the hiatal hernia is reduced,
esophagus encircled and pulled into the abdomen,
esophageal lumen is narrowed, so that RFA elec-
trodes apply more closely to the mucosa. Con-
comitant ARS and RFA was proven to be safe,
not time-consuming, and it was performed in con-
junction with the basic rules of RFA procedure,
avoiding potential pitfall of choosing wrong balloon
diameter.15 To conclude, ARS as the addition to RFA
of BE may play an important role in recurrence pre-
vention, which, however, has to be demonstrated in
sufficiently powered studies.
Alternatives for surgical sphincter
augmentation
The laparoscopic fundoplication is the current sur-
gical gold standard for the treatment of GERD.
A multicenter European trial comparing med-
ical therapy with Nissen or Toupet fundopli-
cation performed in selected centers by expert
surgeons showed that 92% of medical patients and
85% of surgical patients remained in remission at
5 years of follow-up.19 However, despite a remark-
ably low morbidity and mortality rates, fundopli-
cation appears underused due to the perception
of long-term side effects and fear of failure, which
impacts referral patterns.20 Gastroenterologists tend
to limit their referrals for fundoplication only to
patients with long-lasting severe disease and large
hiatal hernias. A downward trend in the utiliza-
tion of surgical fundoplication has been noted in
the United States over the past decade.21–23 Novel
potentially less invasive options for sphincter aug-
mentation will be discussed. Table 1 outlines some
pros and cons of methods discussed.
Do we go magnetic?
Magnetic sphincter augmentation (LINX R© Reflux
Management System) is a U.S. Food and Drug
Administration (FDA)-approved device designed to
provide a permanent solution to GERD by aug-
menting the lower esophageal sphincter (LES) bar-
rier with a standardized laparoscopic procedure that
does not alter gastric anatomy and does not deteri-
orate with time.
The LINX device is a dynamic implant that does
not compress the esophagus and does not limit
its range of motion upon swallowing, belching,
and vomiting. For reflux to occur, the intragastric
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Table 1. A short overview of current pros and cons when using alternative GERD therapies
Pros Cons
LINX Does not limit belching and vomitting




Limited in using MRI postoperative
Foreign body at the EGJ
No RCT data yet
Cost
GerdX Pure endoscopic procedure
Easy procedure
Only for selected patients
No long-term data
Small amount of published data
Contraindicated in (large) hiatal hernias
EsophyX Pure endoscopic procedure
Large amount of published data
(including RCT)
Easy procedure
Only for selected patients
Questionable long-term data
Contraindicated in (large) hiatal hernias
MUSE Pure endoscopic procedure Only for selected patients
No direct vision
Small amount of published data
Technically demanding procedure
Contraindicated in (large) hiatal hernias
EndoStim Supposed to enhance the muscle function
at the EGJ
No risk for dysphagia
Option for patients with severe IEM
Foreign body (abdominal wall and EGJ)
Small amount of published data
Mandatory reoperation after 7 years
Unknown mechanism
Cost
Stretta Pure endoscopic procedure
Low rate of adverse events
Easy procedure
Data appear to be inconclusive
pressure must overcome the resistance to opening of
both the patient’s native LES pressure and the mag-
netic bonds of the device (Fig. 2). The LINX device
is manufactured in different sizes and is capable of
nearly doubling its diameter when all beads are sep-
arated. The Linx device, while augmenting the LES,
allows for expansion to accommodate a swallowed
bolus or the escape of elevated gastric pressure asso-
ciated with belching or vomiting. The LINX device
has recently received magnetic resonance imaging
approval for scanning in systems up 1.5 Tesla. The
device is implanted with a standard laparoscopic
approach under general anesthesia. After minimal
dissection, the circumference of the esophagus is
measured to determine the proper size of the LINX
device to be implanted. The sizing tool is a laparo-
scopic instrument with a soft, circular curved tip
actuated by coaxial tubes through a handset. The
handset contains a numerical indicator that corre-
sponds to the size range of the LINX device. Once the
appropriate Linx device has been selected, it is intro-
duced through the posterior tunnel. The opposing
ends are then brought to the anterior surface of the
esophagus and connected together by engaging the
two clasps. The decision to proceed with a posterior
crural repair depends on the size of the hernia that
is found intraoperatively.
A feasibility study included 44 patients implanted
with the LINX device at four study centers in
United States and Europe between February 2007
and October 2008.24–27 In this study, patients served
as their own control to assess the effect of treat-
ment on esophageal acid exposure, symptoms, and
use of PPI. The primary criteria for inclusion in the
feasibility trial were age >18 and <85 years, typical
reflux symptoms at least partially responsive to PPI
therapy, abnormal esophageal acid exposure, and
normal contractile amplitude and wave form in the
esophageal body. All LINX devices were successfully
implanted via a standard laparoscopic approach.
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The median operative time was 40 (19–104) min and
no intraoperative complications occurred. Thirty-
three patients were followed at 5 years. The mean
total GERD-HRQL score off PPI decreased from
25.7 at baseline to 2.9 at year 5 (P < 0.001), and
94% (31 of 33) of patients had a greater than 50%
reduction in the total score compared to baseline;
91% of patients reported of being satisfied with their
current condition. Esophageal pH testing was com-
pleted in 20 patients at 5 years: 85% of patients
achieved either normal esophageal acid exposure or
had at least a 50% reduction from baseline. Nor-
malization of esophageal pH was achieved in 70%
of patients. Complete cessation of PPI or a reduc-
tion of 50% or more of the daily dose at 5 years
was achieved by 88% and 94% of patients, res-
pectively.
In Milan, Italy, 100 consecutive patients under-
went LINX device implantation between 2007 and
2012. The median implant duration was 3 years,
ranging from 378 days to 6 years. There was a signif-
icant reduction of acid exposure time and improve-
ment of GERD-HRQL score; freedom from daily
dependence on PPI was achieved in 85% of the
patients.28
A recent analysis of the safety profile of the first
1000 worldwide implants in 82 hospitals showed
1.3% hospital readmission rate, 5.6% need of post-
operative endoscopic dilations, and 3.4% reoper-
ation rate.29 Among the 36 patients who had the
device removed, the most common symptoms were
dysphagia and recurrence of reflux symptoms. In
addition, 7% of patients enrolled in the U.S. multi-
center single-arm trial had the device removed due
to persistent dysphagia in four, vomiting in one,
chest pain in one, and reflux in one.30 A recent study
focused on reoperations for LINX device removal
and reported the long-term results of one-stage
laparoscopic removal and fundoplication. Eleven
out of 164 patients (6.7%) who underwent a LINX
device implant were explanted at a later date, mostly
between 12 and 14 months after the index operation.
The main presenting symptom requiring device
removal was recurrence of heartburn or regurgi-
tation in 46%, dysphagia in 37%, and chest pain in
18%. In two patients (1.2%), full-thickness erosion
of the esophageal wall with partial endoluminal pen-
etration of the device occurred. Device removal was
most commonly combined with partial fundoplica-
tion and there were no conversions to laparotomy.31
Figure 3. Image from the small diameter endoscope within the
GerdX device, toward the esophagogastric junction.
In conclusion, long-term studies have now
demonstrated the safety profile of magnetic sphinc-
ter augmentation and its favorable effect regard-
ing long-term GERD control. Today, the LINX sys-
tem appears to be a reasonable alternative option
to treat selected patients with GERD, who are will-
ing to receive a magnetic implant. However, as cur-
rent studies lack blinding or randomization, further
long-term data appear necessary.
Is endoscopic plication a way?
The introduction of magnetic sphincter augmenta-
tion has certainly marked the beginning of a new
era in the surgical treatment of GERD patients.
However, even less invasive endoscopic options for
GERD have been around for nearly two decades
now.32 Whereas some have not withstood clinical
tests due to several reasons, the following short sum-
mary will describe three different available devices,
which are still available and in clinical use. The gen-
eral technical concept of all plication devices is the
endolumenal creation of a serosa-to-serosa plication
using either tags or staples to reinforce an insuffi-
cient “antireflux valve.”
Based on the no longer commercially available
NDO surgical plicator, a significantly modified
endoscopic full thickness plication device was
introduced recently (GerdX, G Surg GmbH, Seeon-
Seebruck, Germany) and was found to improve
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subjective as well as objective parameters at the
1-year follow-up.33 This device is used with a
small diameter endoscope, which is introduced
into the stomach. Along with the device, it can be
retroflexed to manipulate and retract the gastric
cardia into the two arms of the plication tool and
deploying sutures after gathering sufficient tissue.
Multiple sutures are used to create an augmented
antireflux valve (Fig. 3). Refinements of the device
as well as technique are still under investigation.34
The majority of data are currently available on
the transoral incisionless fundoplication (TIF) pro-
cedure using the EsophyX R© device (EndoGastric
Solutions, Redmond, WA). This device also uses a
helical retractor and an additional integrated suc-
tion apparatus to grasp the distal esophagus, deliv-
ering multiple H-shape polypropylene fasteners to
create a 2–3 cm, 270° full thickness esophagogas-
tric fundoplication (Fig. 4A and B). A recently
published systematic review, comparing the TIF
procedure with a PPI/sham control group, found a
significantly higher response rate to TIF.35 However,
no significant difference in the mean percentage of
esophageal acid exposure time was observed. Addi-
tionally, response rate efficacy was found to decrease
over time.
A completely different technology is used by the
MUSETM (Medigus, Omer, Israel) endoscopic sta-
pling system, which consists of built-in video cam-
era, an endostapler, and an ultrasound transducer
(Fig. 5). Under ultrasonic guidance, a stapler is fired
at the level above the esophageal Z-line, which is
repeated several times to form a sufficient fundo-
plication. Recently published data of a multicenter
prospective study found nearly 70% of patients who
remained off PPI after 4 years. The authors also
reported a normalization of pH studies in 37% of
patients after 6 months.36,37
To summarize, endoscopic plication could be
an alternative or also initial therapy for highly
selected patients and later surgical fundoplication
appears not to be impaired.38 Current data, how-
ever, also observed that long-term reflux control
efficacy decreased with time and remains a matter
of further research.
How does electric sphincter stimulation
work?
Electrical stimulation therapy (EST) of the lower
esophageal sphincter (EndoStim R©) is a novel treat-
Figure 4. Schematic pictures of the EsophyX R© device inserted
through the mouth and positioned at the esophagogastric junc-
tion (A) and creating a full-thickness tissue fold (B).
ment of GERD using neurostimulation. The tech-
nology is designed to restore the function of the LES,
thereby reinforcing the barrier against reflux while
preserving normal swallow ability. The treatment
has been shown to be safe and effective in multi-
center, international trials for more than 4 years,
most notably improving/normalizing esophageal
acid exposure.39–42 Additionally, the procedure is
reversible, which is attractive as it does not preclude
another procedure in the future if it is needed.43
Two long-term international trials have been pub-
lished, including 66 patients from 11 centers.39–42
In all patients, GERD was verified at baseline
by esophageal pH testing and validated symptom
questionnaires. In a meta-analysis of the studies,
GERD-health-related quality of life symptom scores
improved significantly compared to both baseline
on-PPI and baseline off-PPI scores.44 Additionally,
89% of patients had discontinued regular PPI use at
their last follow-up and 76% were no longer using
any PPI. The effect is confirmed by a significant and
sustained improvement in a 24-h distal esophageal
acid exposure.
The sustained improvement in esophageal acid
exposure over a 4-year duration, an objective mea-
surement of GERD, indicates the stimulation has
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a sustained effect on LES function. However, more
remains to be learned about exactly which reflux
mechanisms are affected by the neuromodulation.
One mechanism, identified in acute studies, is
increased LES resting pressure resulting from stim-
ulation. In acute studies, significant improvement
of basal pressure was documented in all patients,
with no impact on swallowing function (n = 15).
Importantly, no dysphagia or other gastrointestinal
(GI) side effects were reported despite the increased
tone.45,46
Initial data in patients with esophageal hypo-
motility or aperistalsis who received EndoStim ther-
apy suggest that stimulation may increase peristaltic
propulsion and reducing the duration of reflux
episodes, although the mechanism of this obser-
vation remains unclear. Moreover, the stimulation
does not cause new dysphagia in this challenging
patient group.47
Finally, a significant effect on transient lower
esophageal relaxations (tLESRs) has been reported
in a group of patients evaluated with prolonged
high-resolution manometry before and 3 months
after LES stimulation. A significant reduction in
the total number of tLESRs as well as the num-
ber of tLESRs associated with reflux episodes was
observed, suggesting that the effect of LES stimula-
tion on acid exposure and GERD symptoms is also
mediated by improvement in tLESRs.48
In summary, more research is needed to fully
understand the mechanism of EST at the neuro-
humoral level for GERD. However, preliminary evi-
dence suggests positive therapeutic effect on tone,
function, and transient LES relaxations.
Use of the EndoStim device to treat
PPI-resistant patients with significant
motility disorder
Impaired esophageal motility (IEM) is repeatedly
found in patients who receive functional esophageal
testing for GERD, but its causation is not fully
comprehended.49 In the updated Chicago classifi-
cation, version 3.0, IEM is defined as a distal con-
tractile integral below 450 mmHg·s·cm in more than
50% of swallows, clarifying the discrepancy between
week and failed swallows.50 Especially after laparo-
scopic fundoplication, patients with IEM are likely
to develop postoperative dysphagia and certainly are
a specific challenge for antireflux surgery.51
Figure 5. The MUSE device.
Electrical stimulation therapy of the lower eso-
phageal sphincter (EST-LES) might be an appealing
alternative surgical approach for this patient cohort.
The LES stimulation device itself is an implanted
pulse generator connected to a lead with two
stimulation electrodes (Fig. 6), which are placed
on the anterior side of the esophageal gastric
junction.52 As already mentioned, Rodriguez et al.
could demonstrate in the first study in humans
that EST-LES significantly increases LES pressure.
There was neither an effect on LES relaxation in
response to swallows nor did any patients report
dysphagia.47 The subsequent prospective trial in 25
GERD patients treated with EST-LES without hiatal
repair showed an improvement in quality of life
scores as well as a reduction of acid exposure of the
distal esophagus. None of the patients complained
about GI side effects of bloating, inability to belch,
or dysphagia.53 This absence of GI side effects was
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maintained in the long-term 3-year results pub-
lished recently. Interestingly, four patients decreased
in esophageal acid exposure after a turn-off, but
improved after re-engagement of the stimulation
device.40 In a multicenter trial including 42 patients,
mild-to-moderate dysphagia was reported in only
four patients and resolved without intervention.
Seventeen patients also underwent hiatal repair,
which included the patients with dysphagia. The
short-term results of this trial proved the safety and
efficacy of EST-LES in a multicenter setting.42 The
fact that there is no influence on the swallowing-
induced sphincter relaxation appears appealing for
the use of EST of the LES in patients with IEM.
As surgical technique of EST-LES induces no or
just minimal anatomical alteration, any mechanical
reason for potential later dysphagia is lacking.
Consequently, patients with IEM, eventually at risk
for side effects after laparoscopic fundoplication,
can be considered good candidates for lower
esophageal sphincter stimulation. An ongoing
prospective trial will provide further insight.
Stretta therapy
The endoscopic radiofrequency procedure
(Stretta R©, Mederi Therapeutics, Norwalk, CT) was
approved by the FDA as early as in 2000 to treat
GERD. The Stretta catheter contains a balloon
within a basket, which has needle electrodes to
deliver radiofrequency energy. However, the phys-
iological effect as well its outcome is still contro-
versially discussed. The Stretta system uses
radiofrequency energy delivered to the muscle at
the gastroesophageal sphincter, which is supposed
to induce fibrosis in the muscle tissue, leading to a
less compliant distal esophagus. It is additionally
hypothesized that low-power radiofrequency stimu-
lation results in muscle proliferation and muscle
thickening, which thereby increases the physio-
logical barrier function. In a porcine model, it
has been demonstrated that after Stretta collagen
deposition and fibroblast reaction occur, indicating
fibrotic reaction. This could lead to an increased
lower esophageal pressure and/or a decreased rate
of transient lower esophageal sphincter relaxation.
A recently published systematic review, includ-
ing 2468 patients, revealed that the Stretta
procedure significantly improved subjective and
objective clinical endpoints, without significantly
increasing the LES resting pressure. The adverse
Figure 6. Intraoperative situs after implantation of the stimu-
lation leads on the anterior side of the esophageal gastric junc-
tion. Nylon threads are fixed with two 10-mm titanium clips and
the silicone butterfly is fixed with a 3-0 multifilament thread
(nonabsorbable). A posterior hiatal repair was done prior to
placement of the electrodes.
event rate appeared to be less than 1%. Others
state that randomized sham-controlled trials did
not support the findings of the open-label trials as
level I studies could not sufficiently demonstrate
an improvement of objective parameters. However,
currently published randomized trials did include
only a small number of patients compared to a large
cohort of nonrandomized patients treated by the
Stretta procedure. Larger adequately powered tri-
als could eventually answer these questions more
sufficiently.
To summarize, several alternative therapeutic
options to treat patients with GERD are available
these days. This could not only lead to a more patient
tailored treatment of GERD, but could especially be
beneficial for patients within the therapeutic win-
dow of GERD.
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